These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 24589534)

  • 1. Stakeholders discuss biosimilar naming, substitution.
    Traynor K
    Am J Health Syst Pharm; 2014 Mar; 71(6):446-7. PubMed ID: 24589534
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluating AE Reporting of Two Off-Patent Biologics to Inform Future Biosimilar Naming and Reporting Practices.
    Stergiopoulos S; Getz K
    Drug Saf; 2015 Aug; 38(8):687-92. PubMed ID: 26108298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hot Topics in Primary Care: Demystifying the Differences: Follow-on Biologics, Biosimilars, and Generics.
    Wright EE; Blevins TC; Reed B; Pollom RD
    J Fam Pract; 2017 Apr; 66(4 Suppl):S22-S27. PubMed ID: 28375404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of the FDA draft guidance on biosimilars for clinicians: what we know and don't know.
    Li E; Hoffman JM
    J Natl Compr Canc Netw; 2013 Apr; 11(4):368-72. PubMed ID: 23584340
    [No Abstract]   [Full Text] [Related]  

  • 5. Biosimilars in the Caribbean--key considerations.
    Cox SD
    West Indian Med J; 2012 Dec; 61(9):849-52. PubMed ID: 24020222
    [No Abstract]   [Full Text] [Related]  

  • 6. Perspectives on the Current State of the Biosimilar Regulatory Pathway in the United States.
    Dougherty MK; Zineh I; Christl L
    Clin Pharmacol Ther; 2018 Jan; 103(1):36-38. PubMed ID: 29152721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interchangeability of biosimilars: A study of expert views and visions regarding the science and substitution.
    Druedahl LC; Kälvemark Sporrong S; Minssen T; Hoogland H; De Bruin ML; van de Weert M; Almarsdóttir AB
    PLoS One; 2022; 17(1):e0262537. PubMed ID: 35015783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tildrakizumab-asmn: What's in a Name?
    Yang EJ; Beck KM; Liao W
    Am J Clin Dermatol; 2018 Jun; 19(3):291-292. PubMed ID: 29687361
    [No Abstract]   [Full Text] [Related]  

  • 9. Maintaining 'standards' for biosimilar monoclonal antibodies.
    Prior S; Metcalfe C; Hufton SE; Wadhwa M; Schneider CK; Burns C
    Nat Biotechnol; 2021 Mar; 39(3):276-280. PubMed ID: 33664522
    [No Abstract]   [Full Text] [Related]  

  • 10. Some thoughts on drug interchangeability.
    Chow SC; Song F; Chen M
    J Biopharm Stat; 2016; 26(1):178-86. PubMed ID: 26366703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BIOSIMILAR DRUGS ARE NOT GENERICS.
    Zangeneh F; Dolinar R
    Endocr Pract; 2016 Jan; 22(1):6-7. PubMed ID: 26731083
    [No Abstract]   [Full Text] [Related]  

  • 12. Biosimilars might not measure up to health plan expectations.
    Reinke T
    Manag Care; 2012 Oct; 21(10):12-3. PubMed ID: 23156071
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA issues guidelines for biosimilar drugs.
    Cancer Discov; 2012 Mar; 2(3):196. PubMed ID: 22585973
    [No Abstract]   [Full Text] [Related]  

  • 14. Biosimilar safety factors in clinical practice.
    Reinisch W; Smolen J
    Semin Arthritis Rheum; 2015 Jun; 44(6 Suppl):S9-15. PubMed ID: 26058551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar names for similar biologics.
    Casadevall N; Felix T; Strober BE; Warnock DG
    BioDrugs; 2014 Oct; 28(5):439-44. PubMed ID: 25001080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some thoughts on the QR method for analytical similarity evaluation.
    Son S; Oh M; Choo M; Chow SC; Lee SJ
    J Biopharm Stat; 2020 May; 30(3):521-536. PubMed ID: 32089068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations in the early development of biosimilar products.
    Li EC; Abbas R; Jacobs IA; Yin D
    Drug Discov Today; 2015 May; 20 Suppl 2():1-9. PubMed ID: 25572407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The US Biosimilar Market: Stunted Growth and Possible Reforms.
    Sarpatwari A; Barenie R; Curfman G; Darrow JJ; Kesselheim AS
    Clin Pharmacol Ther; 2019 Jan; 105(1):92-100. PubMed ID: 30415479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In the Biosimilar Marketplace Will There Be 50 Ways to Leave Your Insulin?
    Carter AW
    J Diabetes Sci Technol; 2016 Sep; 10(5):1188-91. PubMed ID: 26817993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The rise of biosimilars: How they got here and where they are going.
    Patel D; Gillis C; Naggar J; Mistry A; Mantzoros CS
    Metabolism; 2017 Oct; 75():45-53. PubMed ID: 28939017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.